Drug · DIN 02041456
ATIVAN
SUBLINGUAL TABLETS
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since July 3, 2026; first marketed December 31, 1995.
- Drug Identification Number (DIN)
- 02041456
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Targeted substances (CDSA IV)
- Dosage form
- Tablet
- Route
- Sublingual
- Therapeutic class (ATC)
- Lorazepam N05BA06
- Class
- Human
- Record last updated
- September 14, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LORAZEPAM | 0.5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 29, 2010: NOC 11751New Drug Submission (NDS) · Manufacturer name change
- April 2, 2003: NOC 1719New Drug Submission (NDS) · Manufacturer name change
Other DINs named ATIVAN
- DIN 02041413 · Cancelled Post Market
- DIN 02041421 · Cancelled Post Market
- DIN 02041448 · Cancelled Post Market
- DIN 02041464 · Cancelled Post Market
- DIN 02041472 · Cancelled Post Market